U.S. FDA approves Biogen's multiple sclerosis drug, Tecfidera
March 27 (Reuters) - U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
Combined clinical trial data showed Tecfidera, formerly known as BG-12, cut the average relapse rate by 49 percent after two years compared to patients taking a placebo.
- Ten countries scour sea for Malaysia jet lost in 'unprecedented mystery' |
- Confrontation in Ukraine as diplomacy stalls |
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Mexico kills drug kingpin reported dead years ago: official
- Pistorius vomits in court at Steenkamp autopsy details |